Back to News
Jan 12, 2026 12:30 PM

Teva Taps Royalty Pharma For $500M To Advance Skin Disease Drug

Teva Pharmaceutical Industries Ltd. (NYSE:TEVA) and Royalty Pharma plc (NASDAQ:RPRX) announced on Sunday a funding agreement of up to $500 million to accelerate the clinical development of Teva’s anti-IL-15 antibody, TEV-‘408.

IL-15 is a key cytokine involved in multiple immune-mediated disease pathways.

Phase 1b data from the ongoing TEV-‘408 vitiligo study provide preliminary support for IL-15 as a potential therapeutic target to treat a wide variety of autoimmune conditions.

Vitiligo is a chronic autoimmune skin disease characterized by the loss of pigment-producing cells (melanocytes), resulting in white patches that can appear anywhere on the body.

Teva anticipates sharing results from TEV-‘408 trials during 2026.

The candidate is ...